Corcept Therapeutics Inc

Corcept Therapeutics faces a double‑whammy: FDA rejects its steroid‑modulator therapy and a securities lawsuit looms, driving a 16% stock plunge and forcing investors to weigh regulatory risks against future upside.

Corcept Therapeutics shares tumble 8% amid a weak Nasdaq; learn how the company’s cortisol‑modulating therapy and high valuation drive volatility and potential upside.

Corcept Therapeutics Inc. is a leading pharmaceutical company that is making significant strides in developing innovative treatments for severe metabolic and psychiatric disorders through its pioneering approach to cortisol modulation.

Corcept Therapeutics Inc. saw a surge in its share price after a Phase 3 clinical trial showed promising results for its drug relacorilant in treating platinum-resistant ovarian cancer.

Corcept Therapeutics’ shares surged after a Phase 3 clinical trial showed promising results for its treatment relacorilant in combination with nab-paclitaxel for platinum-resistant ovarian cancer.